Rhythm Pharmaceuticals, Inc. RYTM Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $217.17M+14.4% | $189.76M+8.8% | $174.33M+11.5% | $156.29M+14.2% | $136.86M+5.2% | ||
| $23M+18.0% | $19.49M+5.5% | $18.48M+9.9% | $16.81M+18.3% | $14.21M+6.3% | ||
| $194.16M+14.0% | $170.27M+9.2% | $155.86M+11.7% | $139.48M+13.7% | $122.65M+5.0% | ||
| 89.4%-0.3pp | 89.7%+0.3pp | 89.4%+0.2pp | 89.2%-0.4pp | 89.6%-0.1pp | ||
| $172.09M+2.8% | $167.34M+0.5% | $166.48M+5.1% | $158.38M+8.3% | $146.27M-38.5% | ||
| $219.44M+12.6% | $194.94M+11.0% | $175.59M+10.8% | $158.54M+6.4% | $149.01M+3.3% | ||
| $414.54M+8.6% | $381.77M+5.9% | $360.54M+8.0% | $333.73M+7.8% | $309.49M-21.8% | ||
| -$197.37M-2.8% | -$192.02M-3.1% | -$186.21M-4.9% | -$177.44M-2.8% | -$172.62M+35.0% | ||
| -90.9%+10.3pp | -101.2%+5.6pp | -106.8%+6.7pp | -113.5%+12.6pp | -126.1%+77.9pp | ||
| $19.76M-4.0% | $20.58M-3.9% | $21.42M-2.3% | $21.92M+5.9% | $20.7M+3.3% | ||
| $15.21M-0.6% | $15.29M+3.9% | $14.72M+1.9% | $14.45M-5.6% | $15.31M+4.0% | ||
| -$4.35M-7.9% | -$4.03M— | —— | —— | —— | ||
| -$201.72M-2.9% | -$196.04M-2.2% | -$191.89M-4.8% | -$183.08M-8.6% | -$168.57M+35.2% | ||
| $993K+88.1% | $528K— | —— | —— | —— | ||
| -$202.68M-3.1% | -$196.54M-2.2% | -$192.33M-5.1% | -$183.06M-8.5% | -$168.69M+35.3% | ||
| -93.3%+10.2pp | -103.6%+6.7pp | -110.3%+6.8pp | -117.1%+6.1pp | -123.3%+77.0pp | ||
| -$3.13-0.6% | -$3.11-0.3% | -$3.10-3.0% | -$3.01-7.1% | -$2.81+35.4% | ||
| -$3.13-0.6% | -$3.11-0.3% | -$3.10-3.0% | -$3.01-7.1% | -$2.81+35.4% | ||
| 262.9M+1.9% | 258M+1.6% | 254M+2.0% | 249M+1.1% | 246.3M+1.2% | ||
| 262.9M+1.9% | 258M+1.6% | 254M+2.0% | 249M+1.1% | 246.3M+1.2% | ||
| -$206.24M-1.8% | -$202.67M-2.3% | -$198.03M-4.2% | -$190.03M-9.3% | -$173.86M+34.3% | ||
| $5.16M-4.1% | $5.38M-0.1% | $5.39M+0.9% | $5.34M+0.9% | $5.29M+33.3% | ||
| $15.21M-0.6% | $15.29M+3.9% | $14.72M+1.9% | $14.45M-5.6% | $15.31M+4.0% | ||
| -$30K-106% | $504K+1,967% | -$27K-127% | $100K+69.5% | $59K+134% | ||
| $514K+140% | -$1.27M-331% | -$295K+83.0% | -$1.73M-2,538% | $71K+3,450% | ||
| $203K-83.9% | $1.26M-17.5% | $1.53M-34.7% | $2.35M+119% | $1.07M-52.2% | ||
| $217.17M+14.4% | $189.76M+8.8% | $174.33M+11.5% | $156.29M+14.2% | $136.86M+5.2% | ||
| -$197.37M-2.8% | -$192.02M-3.1% | -$186.21M-4.9% | -$177.44M-2.8% | -$172.62M+35.0% | ||
| —— | —— | —— | —— | —— | ||
| -$197.37M-2.8% | -$192.02M-3.1% | -$186.21M-4.9% | -$177.44M-2.8% | -$172.62M+35.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s revenue?
- Rhythm Pharmaceuticals, Inc. (RYTM) generated $217.2M in revenue over the trailing twelve months, up 58.7% year over year.
- Is Rhythm Pharmaceuticals, Inc. profitable?
- Rhythm Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $202.7M over the trailing twelve months, a -93.3% net margin.
- What are Rhythm Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 89.4% and operating margin is -90.9%, with a -93.3% net margin.
- What is Rhythm Pharmaceuticals, Inc.'s earnings per share?
- Rhythm Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-3.13.
- Where does Rhythm Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Rhythm Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
